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Abstract
 
INTRODUCTION: Standard treatment for atrial tachyarrthmias, such as atrial fibrillation or 
atrial flutter, involves rate and rhythm control.  Previous studies have looked at the 
electrophysiologic effects of magnesium on impulse formation and propagation, and 
theorized it could be beneficial in treatment for atrial tachycardias.   There recently have 
been studies about magnesium sulfate and its utility in establishing rate and rhythm 
control in patients with atrial fibrillation or flutter.  METHODS:  This systematic review 
used several databases to find five relevant articles regarding the use of intravenous 
magnesium sulfate in non-postoperative patients with atrial fibrillation or atrial flutter.  
The articles’ outcomes were ventricular rate control and return to normal sinus rhythm.   
Only randomized control trials that were double or single-blinded were used to ensure 
validity.  RESULTS:  Both studies that used magnesium sulfate bolus and infusion in 
conjunction with an antiarrhythmic medication such as a beta blocker, calcium channel 
blocker, or digoxin, had better ventricular rate control. Only one of the two studies using 
magnesium sulfate with an antiarrhythmic medications had a better conversion to normal 
sinus rhythm. Of the three studies that did not use antiarrhythmic medication with 
magnesium sulfate, the study that used only use a bolus of magnesium sulfate did not 
have a beneficial effect in rate or rhythm control.  The other two studies that did use a 
bolus and infusion of magnesium sulfate, but no other antiarrhythmics, had better 
efficacy in returning the patient to a normal sinus rhythm.  CONCLUSION:  Magnesium 
sulfate, in conjunction with typical antiarrhythmics, given as a bolus and infusion is 
found to have greater efficacy in ventricular rate control and return to normal sinus 
rhythm.  Further randomized control trials regarding specific dose of magnesium sulfate 
and antiarrhythmic medication needs to be pursued.  
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INTRODUCTION 
  
 Any sinus rhythm at a rate higher than one hundred beats per minute is considered 
supraventricular tachycardia, and atrial tachyarrhythmia is a specific type of 
supraventricular tachycardia. 1  Atrial tachyarrhythmias originate in the atria and sustain a 
rate greater than one hundred.  Abnormal impulse formation or propagation is the cause 
of atrial tachyarrhythmias. 2  
 Normal impulses are formed due to the heart’s automaticity, which is caused by 
an action potential within the cardiac myocyte.3 The action potential allows the sinus 
node to depolarize, which then causes a heartbeat. The normal action potential of a 
cardiac myocyte has five different sequential phases.  Each one of the phases represents 
different ions crossing the cell membrane of the cardiac myocyte.3 Phase 0 is 
depolarization by sodium ions crossing over the cell membrane into the myocyte.3 Slight 
repolarization in Phase 1, is due mostly to potassium ions leaving the cell.  Phase 2 
utilizes calcium and potassium.  Calcium travels into the cell while potassium is still in a 
slow outward flux.3 Phase 3 is where most of the repolarization occurs, because more 
potassium is leaving the cell than calcium is entering.  The resting phase of the action 
potential is in Phase 4.  The sodium-potassium adenosine triphophatase pump and 
sodium-calcium exchanger maintains Phase 4 of the action potential in the cardiac 
myocyte. The pump and exchanger return the balance of ions to their original state.3 
 Normal impulse formation reaches threshold potential and then depolarizes 
spontaneously in the sinoatrial node.  This process is called automaticity.3 Other cells 
such as the atrial cells, atrioventricular node, and the His-Pukinje fibers are capable of 
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automaticity if they are not suppressed by the more rapid firing sinoatrial node.3 The 
slope of Phase 4 and threshold potential determine the rate of impulse formation, and are 
regulated by the autonomic nervous system and ionic currents .2  
  Normal propagation of a cardiac impulse originates from the sinus node; the 
sinus node activates first the atria, then atrioventricular node, then bundle of His, then 
bundle branches, and finally, the ventricles.  4This systematic traveling impulse allows 
for the atria to contract first and adequately fill the ventricles to maximize cardiac 
output.3 
  There are two reasons why a patient would experience an atrial tachyarrythmia,  
abnormal impulse formation or abnormal impulse propagation. In case of abnormal 
impulse formation, this could be from a decreased threshold for the action potential. 
When the slope of phase 4 of the cardiac action potential is increased, this causes aberrant 
automaticity and reduces the threshold for the action potential.2  Electrolyte abnormalities 
can cause deviations in the cardiac myocyte action potential.   Abnormal propagation in 
atrial tachyarrhythmias could be due to reentry. 4  Reentry is the phenomenon where a 
group of muscle fibers fails to be initially activated during normal wave propagation, but 
are activated in the retrograde direction by the same wave of depolarization.4 Atrial  
fibrillation is the most common tachyarrhythmia, and is characterized by uncoordinated 
atrial electrical activation and atrial contraction. 53   It is estimated that at least five 
million Americans have been diagnosed with atrial fibrillation.3 The prevalence of atrial 
fibrillation increases with age, with more men than women being affected.  The 
prevalence has been found to be higher in whites than in blacks.4   
 5 
  Atrial fibrillation has a specific etiology and pathology.   Hypertension, coronary 
artery disease, heart failure, and valvular heart disease are usually associated with and 
thought to be a cause of atrial fibrillation.6  4  Rheumatic fever once played a greater role 
its etiology, but successful prevention of the disease has limited its role. 4  The two 
mechanisms that lead to the development of atrial fibrillation are abnormal impulse 
formation from rapidly firing foci which hit the atrioventricular  node, and abnormal 
impulse propagation caused by multiple reentry circuits in the atria. The source of the 
rapidly discharging foci usually arises from the pulmonary veins that cause abnormal 
automaticity.4  Pulmonary veins in patients with atrial fibrillation have shorter refractory 
periods than healthy patients in control groups. 4 Ionic changes due to altered atrial 
myocytes from stretched myocardial muscle can also lead to abnormal impulse 
formation.3  The repeated stimulation of the atrioventricular node causes an irregular, 
rapid ventricular response. 5   
 The second possible cause of atrial fibrillation is reentry due to multiple wavelets. 
The initial impulse travels around refractory tissue and become irregular wavelets that 
then can accelerate or decelerate upon encountering other tissue.4 Larger atrial mass is 
correlated with more refractory tissue.4 The normal progression is atrial tissue alteration 
due to heart disease or normal aging,  leads to sinus node damage, and eventual atrial 
fibrillation.4  
 In the case of atrial flutter, there is a regular rhythm has monomorphic P waves, 
no isoelectric baseline, and a rate of 240 to 340 beats per minute.4  The problem arises 
when a single macroreentry circuit in the right atrium leads to regular, but rapid, 
ventricular response.5  Basically, there is a narrow region of reentrant demarcated by 
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anatomic or functional barriers which can be from past surgical scars or nonsurgical 
fibrosis that generate reentrant pathways allowing atrial flutter, most often induced by a 
premature atrial beats, to occur.43 A patient is most commonly at risk for atrial flutter 
within one week after open heart surgery.  Other diseases associated with atrial flutter are 
chronic obstructive pulmonary disease, mitral or tricuspid disease, atrial enlargement, and  
thyrotoxicosis.3 
 Atrial tachyarrhythmias can be asymptomatic or can produce symptoms such as 
palpitations, syncope, chest pain, shortness of breathe, dizziness, or a sense of a slowing 
heart rate. 2   These symptoms are produced when there is decreased ventricular filling, 
which then causes a decreased cardiac output. 2 Conditions such as atrial fibrillation or 
flutter are diagnosed by electrocardiogram (ECG).  An echocardiogram is sometimes 
performed to monitor cardiac chamber size and function and valve abnormalities.2 
 There are several appropriate treatment modalities for atrial tacyarrhythmias.  The 
standard treatments for atrial fibrillation, alone or in combination, are ventricular rate 
control, rhythm control, and prevention of thromboembolism.4. To establish ventricular 
rate control, beta-adrenergic blockers, calcium channel blockers, or digoxin are useful.4 
Normal sinus rhythm can be restored or maintained either pharmacologically or 
electrically.4 Flecainide, dofetilide, propafenone, ibutilide, or amiodarone can be used in 
chemical cardioversion.  External synchronized DC cardioversion and radiofrequency 
catheter ablation are modalities for electrical cardioversion. The risk of thrombolytic 
events can be decreased by keeping the international normalized ration (INR) between 
2.0 and 3.0 with an anticoagulant.4 
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 For atrial flutter, the treatment modalities are also pharmacologic or electricic 
Effective chemical cardioversion can be achieved with type IC antiarrhythmics  in 
combination with atrioventricular nodal blocking agents like beta adrenergic blockers, 
type III antiarrhythmics, such as sotalol, dofetilide, ibutelide, and amiodarone, or class IA 
antiarrhythmics, for example quinidine, procainamide, or disopyramide.5 4  Electrical 
cardioversion involves overdrive pacing of the atria or direct current synchronization to 
the QRS complex.4 Catheter ablation is another option for the treatment of atrial flutter.4  
There is a question when dealing with patients with atrial flutter as to whether efforts 
should be made to prevent thromboembolism as their risk is lower than those diagnosed 
with atrial fibrillation.  However, there has been recent evidence of thrombogenic 
potential in patients with atrial rates greater than two hundred.4   
 
Magnesium Sulfate 
 
 Magnesium is an intracellular ion that participates in more than three hundred 
enzymatic reactions within the body, and is involved closely with the production and 
utilization of adenosine triphosphate.7  Patients with low intracellular levels of 
magnesium are predisposed to cardiac arrhythmias, as magnesium is needed for 
potassium and calcium channels to function properly in the myocardial cell.7  Magnesium 
is an important cofactor into the sodium-potassium adenosine triphosphate pump for 
Phase 4 of the cardiac action potential, accordingly it is standard treatment to give 
magnesium salts to patients with refractory ventricular arrhythmias. 3 8   
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 Magnesium sulfate has historically been used to treat ventricular arrhythmias such 
as ventricular fibrillation or pulseless ventricular tachycardia in patients with suspected 
hypomagnesemia under the theory that hypomagnesemia can precipitate ventricular 
fibrillation and hinder the return of potassium to the myocytes.  4. 4 Magnesium 
imbalances may cause aberrant cardiac impulse generation and reentrant loop in the 
atria.6   
 Recent studies have looked at the electrophysiological effect of magnesium on 
cardiac myocytes.910  The first electrophysiologic study compared magnesium sulfate to 
adenosine triphosphate for treating supraventricular tachycardia. 9 It was hypothesized 
that, since magnesium sulfate prolongs atrioventricular node conduction and 
refractoriness, it could be used for atrioventricular node reentrant supraventricular 
tachycardias.  It was concluded  that magnesium sulfate did not terminate 
supraventricular tachycardias, but it did show some promise in blocking retrograde 
conduction in accessory pathways.  
 The second study looked at the differential effects of intravenous magnesium on 
atrioventricular node conduction in twenty-three patients with supraventricular 
tachycardia.10 Patients were given 2.47 grams of intravenous magnesium sulfate bolus 
over one minute.  The study found that magnesium sulfate prolongs tachycardia cycle 
length in patients, from 340 to 370 milliseconds (8.8%) versus patients without 
magnesium sulfate from 347 to 350 milliseconds (0.8%), when compared to baseline.  
Since lengthening the tachycardia cycle length will delay the atrioventricular node 
conduction, and thereby decrease the number of impulses going to the ventricles, this will 
cause a decrease in ventricular rate.   These two electrophysiologic studies have shown 
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that magnesium sulfate has the potential to stop retrograde reentry and slow cardiac 
conduction of patients in atrial fibrillation or atrial flutter.  
 Two retrospective studies that looked at the efficacy of ibutilide with or without 
magnesium sulfate found it efficacious in rate and rhythm control in patients with atrial 
fibrillation and atrial flutter. 1112 Both of the trials had an intervention consisted of 
intravenous magnesium sulfate two hours before or during ibutilide administration.  The 
comparison was no magnesium sulfate, only the ibutilide. The first study had 229 patients 
with atrial fibrillation or atrial flutter received ibutilide for acute chemical conversion 
made up the study group. 11  The trial found successful chemical conversion within six 
hours of ibutilide dose was seventy-eight percent with any dose of magnesium sulfate, 
compared to 59.8% with only ibutilide.  The second retrospective trial had a population 
of 321patients with supraventricular tachycardia who received ibutilide for acute 
chemical conversion. 12  The study found magnesium sulfate enhanced the effect of 
ibutilide to establish rate control after six hours.   Seventy-two percent of patients that 
received magnesium sulfate had a successful chemical cardioversion versus only sixty 
percent of patients that didn’t receive magnesium sulfate. 
 
   
Purpose 
 
 The purpose of this systematic review is to determine whether the addition of 
intravenous magnesium sulfate aids in rate or rhythm control in patients with atrial 
fibrillation or atrial flutter.  There are no current formal recommendations for the use of 
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magnesium sulfate in these particular arrhythmias, and its use is inconsistent in the 
medical community.  There have been several studies of its utility  of the past two 
decades in the management, of atrial tachyarrhythmia.  
 
Hypothesis 
 
 Since most atrial tachyarrhythmias are due to abnormal impulse formation and 
propagation, and since magnesium is utilized by the cardiac myocyte action potential to 
control impulse formation and propagation, magnesium sulfate should therefore, improve 
rate or rhythm control.   Magnesium plays a role in Phase 4 the action potential in a 
cardiac myocyte by being a cofactor in the sodium-potassium adenosine triphosphatase 
enzyme, and by its involvment in the calcium channels in the atrial myocytes. If the 
magnesium is already depleted, or becomes depleted due to the arrhythmia, it would 
make sense that replenishing this electrolyte would assist in the treatment of atrial 
tachyarrhythmia. 
 It would not be expected that magnesium sulfate to chemically cardiovert patients 
in atrial fibrillation or atrial flutter.  However, it seems probable that it could be used in 
conjunction with other antiarrhythmics to provide a higher  rate of  successful conversion.   
 Magnesium sulfate may be able to be used to establish ventricular rate control by 
itself in patients with atrial arrhythmias, but it would most likely have a greater effect 
when used in combination with other rate controlling medication.   
   
Significance 
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 Atrial fibrillation and flutter are common types of arrhythmias that can result in  
serious complications.  If left untreated, they can lead to electrophysiologic remodeling, 
which would predispose the heart to perpetuation of atrial fibrillation.4  Atrial fibrillation 
can also lead to loss of atrial myocardium with scarring and fatty infiltration.4  
Eventually, heart failure can worsen from the added stress on the heart when it has a 
chronically decreased cardiac output.2  Restoring the heart to normal sinus rhythm or to a 
controlled ventricular rate, is crucial to the cardiovascular health of the patient.   
 Atrial fibrillation and atrial flutter confer an increased relative risk of mortality  
most commonly due to stroke.3  The risk of stroke is correlated with increased age in 
patients with atrial fibrillation.3 
 
 
METHODS 
 
 The search for relevant studies was detailed and exhaustive.  Bibliographic 
databases used were MEDLINE-OVID, PUBMED, CINALH, and Web of Science. Only 
published articles were included. The terms searched to allow a comprehensive and 
representative review were (1) “supraventricular tachycardia” ; (2) “magnesium sulfate”; 
(3) “magnesium sulphate”; (4)“atrial fibrillation”; (5) “ atrial flutter”; (6) atrial 
arrhythmia;  (7) or a combination of these terms. 
 Inclusion criteria for these selected studies are any type of atrial tachyarrhythmia, 
including atrial fibrillation or atrial flutter. Patients considered in this systematic review 
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had atrial tachyarrhythmia which was acute or chronic, since most studies were vague 
about the duration of arrhythmia.   Any dosage of intravenous magnesium sulfate was 
included. Studies that used other common antiarrhythmic medications, in addition to the 
magnesium sulfate, were used for the review.   The desired outcome was a decrease in 
heart rate and a conversion to normal sinus rhythm.  Randomized, double-blinded, and 
single-blinded studies were included.  Data from 1990 to the present was used and only 
full articles in English were accepted. 
 Exclusion criteria included patients without atrial tachyarrhythmia, as well as 
patients less than one month postoperative from a cardiac or vascular surgery.  Any study 
done before 1990 was not included in the systematic review.  Commentaries, 
retrospective studies, and case studies were not included in this review.  Validity was 
established by accountability for all patients in the studies, as well as similarity between 
groups at the start of the trials.  Abstracts were not accepted.  A Jadad score equal or less 
than 2 was not accepted for randomized control trials.  (See Table 1 for Jadad Score.)  
 
 
RESULTS 
 
  A total of five articles were used for the systematic review.  Three of the trials 
were double-blinded, randomized controlled trials, and looked solely at atrial 
fibrillation.131415  Two of the articles were single-blinded, randomized controlled trials 
performed on patients with atrial flutter or fibrillation.1617 All of the articles looked at the 
use of intravenous magnesium sulfate and the efficacy of rate and rhythm control in 
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patients with non-postoperative atrial tachyarrhythmias.  The articles were reviewed 
specifically for their study type, sample size, type of arrhythmia, duration of arrhythmia, 
dose of magnesium sulfate, dose of medication with which it was being compared, the 
reduction in ventricular rate, and the conversion to normal sinus rhythm. (See Table 1).  
 The first study looked at magnesium sulfate versus placebo for the treatment of 
paroxysmal atrial fibrillation. 13 The study had forty-eight adults, eighteen years of age or 
older, with atrial fibrillation with an onset of less than forty-eight hours and with a 
sustained ventricular rate greater than one hundred beats per minute.  The intervention 
was intravenous magnesium sulfate 2.5g over fifteen minutes compared to the placebo of 
normal saline.  After two hours, there was no difference between intravenous magnesium 
sulfate and normal saline with regard for decreasing heart rate. For the magnesium sulfate 
group, the ventricular rate dropped by nine beats per minute versus the placebo group that 
showed a drop of twenty-six beats per minute.  The P value was 0.124, which means the 
decrease in heart rate was not statistically significant.  Of the magnesium sulfate group, 
8.7% converted to normal sinus rhythm and 25.0% of the placebo group converted to 
normal sinus rhythm within the same time frame.  The P value for rhythm conversion was 
0.25, which means the outcome was not statistically significant. 
 The next study was a randomized, double-blinded control trial that looked at the 
effect of magnesium sulfate on ventricular rate control in atrial fibrillation in fifteen 
adults with newly recognized atrial fibrillation with a rapid ventricular response.  15  
Patients were given a two-gram bolus of intravenous magnesium sulfate over one minute, 
then four grams over four hours.  The placebo group was given no magnesium sulfate. 
All patients were given 0.5mg of intravenous digoxin after thirty minutes.  This study 
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found that magnesium sulfate decreased the ventricular rate more than the placebo after 
3.5 hours. After five minutes, the heart rate declined seventeen percent in patients that 
were administered the magnesium sulfate compared to one percent in the placebo group 
in the same time period.  The P value was 0.02, which was statistically significant.  Once 
digoxin was administered thirty minutes later to both groups, the magnesium sulfate 
group had a twenty seven percent decrease in heart rate, versus the placebo group which 
had only an eighteen percent rate reduction. The P value was 0.08, which is not statically 
significant. Those patients who returned to normal sinus rhythm were excluded in the 
study; three from the placebo group and one from the magnesium group. The rate of 
conversion of the magnesium group after digoxin was administered was 14.2% and was 
37.5% for the placebo.  
 The next double-blinded, randomized control trial studied the addition of 
magnesium sulfate to the usual care of atrial fibrillation for rate control.  14  One hundred 
and ninety-nine patients, eighteen and older,  suffering from atrial fibrillation with a rapid 
ventricular response greater than 120 beats per minute were included.  Patients were 
randomized to receive intravenous magnesium sulfate in a five gram bolus, followed by 
2.5 grams in twenty minutes, and finally 2.5 grams over two hours or a placebo regimen 
that had no magnesium sulfate.  The study found magnesium sulfate, in conjunction with 
standard therapy for atrial fibrillation, was more apt to decrease the heart rate to less than 
one hundred beats per minute after two and a half hours and to convert to sinus rhythm 
versus no magnesium sulfate.  Sixty-five percent of patients that took magnesium sulfate 
had a favorable outcome versus only thirty-four percent of patients taking the placebo.  
The relative risk was 1.89 with a 95% confidence interval of 1.38 to 2.59; the P value was 
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less than 0.0001.  Twenty-seven percent of patients receiving magnesium sulfate 
converted to normal sinus rhythm compared to twelve percent with placebo.  The relative 
risk was 2.20 with a 95% confidence interval of 1.15 to 4.21; and the P value of less than 
0.01. 
 The next randomized, single-blinded trial studied intravenous magnesium sulfate 
versus diltiazem in paroxysmal atrial fibrillation.16 The population was forty-six patients 
with atrial fibrillation that received intravenous magnesium sulfate bolus of 2.5g over 
fifteen minutes and 7.5g infusion over the next six hours or intravenous diltiazem bolus 
of  25mg over fifteen minutes, then an infusion of 12.5 mg over six hours. After six 
hours, there was no difference in heart rate reduction between the two groups, but both 
did see a statistically significant decrease.  The P value was less than 0.001 at six hours. 
There was a fifty-seven percent conversion rate to normal sinus rhythm in the magnesium 
sulfate group opposed to twenty-two percent of patients who received diltiazem.  It 
appears that magnesium sulfate helps with ventricular rate control and conversion to 
normal sinus rhythm in patients with atrial fibrillation  after twelve hours.   Although 
diltiazem helped with rate control as much as magnesium sulfate, it didn’t have as high a 
rate of conversion to normal sinus rhythm.   
 The final study was a randomized, single-blinded trial that reviewed the effect of 
magnesium versus verapamil on atrial tachyarrhythmias.17 The sixty-four patients 
included in the trial had atrial fibrillation or atrial flutter of a duration of less than one 
week.  Patients were given intravenous magnesium sulfate at a dose of 1.2 grams over 
five minutes, and the same dose was repeated over ten minutes if there was no response.  
After the boluses, an infusion of magnesium sulfate was started at a rate of 0.6 grams per 
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hour.  The control group was given an intravenous verapamil bolus of five milligrams 
over a five minute period, then five milligrams after ten minutes if there was no response.  
Verapamil was then infused at a rate of 0.6 milligrams per hour.  After four hours, 
conversion to normal sinus rhythm occurred in 57.1% of patients who received 
magnesium sulfate versus 12.5% who received verapamil.  A ventricular rate of less than 
one hundred was achieved in 23.8% percent of the magnesium sulfate group versus 
58.3% of those treated with verapamil,  demonstrating that magnesium sulfate was better 
at converting atrial tachyarrythmias than verapamil, yet verapamil was better at 
decreasing the ventricular rate to under one hundred beats per minute than was 
magnesium sulfate.  
 
 
DISCUSSION 
 
 The goal of this literature review was to use current medical literature to 
determine whether intravenous magnesium sulfate was beneficial for patients with new 
onset atrial fibrillation or flutter.  The inclusion and exclusion criteria set forth during the 
search limited the available studies to only a few and made it necessary to include two 
trials that were single-blinded. The Chu study was a double-blinded, randomized clinical 
trial with a Jadad score of five. The methods of randomizing and blinding were well 
explained.  The Jadad score for the Hays study was a three since the methods of 
randomization and blinding were not described, and validity was in question. The Davey 
study was a double-blinded, randomized control trial, and its methods were described in 
 17 
detail, earning a Jadad score of five.  The Gullestad study was a single-blinded, 
randomized trial with a Jadad score was three.  The Chiladakis trial, with a low Jadad 
score of two, was also a single-blinded, randomized trial. 
 The characteristics of each study’s population varied slightly,  as did its size.  All 
of the trials used adults eighteen or older, and some had no upper age limit stated.  The 
average age of a participant was 63.5 years old and only two studies had a significantly 
different average age.  The Chu and Davey study had an average age of fifty-two and 
seventy-two, respectively.  Population sizes ranged from fifteen to 199 patients, and the 
median population size was forty-eight for the five trials. The Hays study had the lowest 
number of participants. 
 The dose of magnesium sulfate varied for each study.  Some studies used boluses, 
some had boluses plus an infusion.  The Chu study was the only trial without an infusion 
of magnesium sulfate after the initial bolus.  The Gullestad study had the smallest bolus 
of magnesium sulfate at 1.2 grams.  The Chiladakis study had the longest infusion of 
magnesium sulfate, at six hours.   
 Some of the studies looked at magnesium sulfate use in conjunction with an 
antiarrhythmic or with other medications. For the Chu study, magnesium sulfate was not 
used in addition with other antiarrhythmic medication while, in the Hays study 
magnesium sulfate was given with digoxin.  The Davey study used a variety of other 
antiarrhythmics with magnesium sulfate at the physician’s discretion versus one standard 
therapy.  The Chiladakis study compared magnesium sulfate with diltizem, but did not 
use an antiarrhythmics in addition to the magnesium sulfate.  The dose of diltiazem was 
maximized in the Chiladakis study. In the Gullestad study, the verapamil dose was small 
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and not titrated. and the magnesium dose was given alone, rather than in conjunction with 
another medication.   
 Not all the studies looked at the same outcome nor the same period of time. The 
Chu study only looked at rate control, and conversion to normal sinus rhythm two hours 
after the intervention.  For the Davey study, the outcomes measured were, the ventricular 
rate control and rhythm conversion after 2.5 hours. In the Hays study, ventricular rate 
control was measured after 3.5 hours, and those that converted to normal sinus rhythm 
were subsequently excluded.  The Chiladakis study only looked at the first six hours for 
rate or rhythm control.  It is possible for both magnesium sulfate and diltiazem to work 
up to twenty-four hours after administration, and this study did not take that into account.  
The Gullestad study looked at both outcomes after four hours. 
 It was predicted that magnesium sulfate given without the addition of an 
antiarrhythmic, would not significantly decrease ventricular rate or convert the 
arrhythmia to a normal sinus rhythm. The Chu study concluded that magnesium sulfate 
alone did not cause significant ventricular rate control or return of normal sinus rhythm.  
The Hays trial exclude patients that converted to normal sinus rhythm, but it does appear 
that the control group had a better rate of conversion.   The Davey study found the use of 
magnesium sulfate, in addition to other antiarrhythmic medication, was efficacious in 
controlling the ventricular rate and returning the rhythm to normal sinus. The Chiladakis 
and Gullestad trials actually found magnesium sulfate alone could increase the number 
converted to normal sinus rhythm. However, both studies failed to control ventricular 
rate. 
 .  
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LIMITATIONS 
 
 
 There were several limitations for this systematic review.  The weakness of this 
systematic review is the broad population.  All patients with chronic or paroxysmal atrial 
tachyarrhythmia were included. The validity of the results this systematic review may 
have been easier to validate in a more specific population, for example had the population 
been limited to those with either atrial fibrillation or atrial flutter.  Most studies appeared 
to be on patients with acute onset atrial tachyarrhythmia.  However, the underlying 
pathophysiology of atrial fibrillation and atrial flutter is similar in nature, making this 
diverse population pertinent.  Ventricular arrhythmias or other supraventricular 
tachycardias were not included, since their pathophysiology is quite different to an atrial 
tachyarrhythmia.   
 Either a decreased ventricular rate or rhythm control was accepted as an outcome. 
This endpoint was not very specific, nor was it an easy endpoint to measure.  Another 
area that could decrease the validity the studies of this review is the range of dosage of  
intravenous magnesium sulfate in each of the studies.  The bolus range was between 1.2 
and 5 grams . Some studies included an infusion of magnesium sulfate as well as a bolus, 
and those ranges also varied.  The discrepancy between dosages could vary the outcomes 
significantly.  The timing of the bolus and infusion of the magnesium sulfate also could 
affect the endpoint.  The bolus of the magnesium sulfate varied, as did the infusion of the 
medication. 
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 The comparison was magnesium sulfate versus no magnesium sulfate (placebo, 
saline, or other medication).  
 The studies selected for this review were not all double-blinded, randomized 
control trials. However, all of them appear to be legitimate in their blinding and 
randomizing.  Certain articles state they are randomized or blinded, but fail to explain 
how that was achieved  and their Jadad score of less than five reflect this.  
 By applying less strict criteria to their outcomes, some of the studies tended to 
overestimate the efficacy of magnesium sulfate. If the endpoint was not precise and 
ventricular rate was just stated as lowered instead of below an exact beat count per 
minute, the study may actually overestimate have over-exaggerated the effectiveness of 
the medication.  For example, the Davey study is alone in having a specific outcome that 
looked at a ventricular rate of less than one hundred beats per minute.  
  The heterogeneity of the populations is the degree of difference between 
the groups and is defined as the P value.  If the P value is less than 0.05 (or saying there 
is one in five hundred chance of these being just a coincidence), the heterogeneity is 
small and makes chance an unlikely explanation for the differences.   Heterogeneity tests 
are less meaningful if the sample sizes are small.  A P value of less than 0.05 is 
statistically significant, meaning that the results are unlikely to be due to chance alone.   
 Recommendations for further study would primarily look at the dosing of 
magnesium sulfate. Finding an optimal dose for the bolus and infusion of magnesium 
sulfate would make the comparison to other medications more standard across the board. 
 
CONCLUSION 
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 Magnesium sulfate has a history in treating ventricular arrhythmias and has 
recently been studied to look at its efficacy in rate and rhythm control in atrial 
tachyarrhythmias.    
  The use of magnesium sulfate is beneficial in the treatment of atrial fibrillation 
and atrial flutter if it is used in conjunction with another antiarrhythmic medication.  
Magnesium sulfate tends not to be as effective in chemical cardioversion or rate control 
when administered by itself.  At least a two milligram bolus of magnesium sulfate 
followed by an infusion leads to higher likelihood of cardioversion.  A dose of four 
milligrams appears to be even more efficacious than lower doses at cardioversion. 
Magnesium sulfate alone was not as effective as verapamil or diltiazem in lowering the 
ventricular rate.   
 More randomized control studies need to be done on the dosage of magnesium 
sulfate.  The optimal amount and rate of the bolus and infusion need to be established 
before further comparisons are made.  Studies comparing different antiarrhythmic 
medications in combination with magnesium sulfate for the treatment of atrial 
tachyarrhythmias would also be useful. 
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FIGURES 
 
 
 
 
FIGURE 1 
 
Jadad scores  
1. Was the study described as randomized? Yes:1 No: 0 
2. Was the method used to generate the sequence of randomization 
described adequately? Yes:1 No: 0 
3. Was the study described as double-blind? Yes:1  No:0 
4. Were those lost to follow-up adequately addressed? Yes:1 No:0 
5. Deduct one point if the method of randomization was described but 
was not appropriate. Yes:-1 No or N/A:0 
6. Deduct one point if the method of blinding was described but was not 
appropriate. Yes: -1 No or N/A:0 
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TABLE ONE 
 
Study 
Study 
Design 
Jadad 
or SS 
Score 
# of 
Pts 
Type of 
Arrhythmia 
C, A, or 
specific 
time 
Dose of 
MgSO4 
Comparison/ 
Control 
Other med 
used with 
MgS04 
Change in 
VR w/ 
MgS04 
Change in 
VR w/ 
Control 
Conversion 
rate to NSR 
w/ MgS04 
Conversion 
rate to NSR 
w/ Control 
Chu DB, R 5 48 AF <48 hrs 2.5g  x 15 min Placebo 
No At 2 hrs, 9 
bpm 
At 2 hrs, 
26 bpm 8.7% 25% 
Davey 
DB, R 
5 
199 AF A 
5g B,  2.5g 
x 20 min, 
2.5g x 2 hrs   
Placebo 
BB, 
verapamil 
or digoxin 
65% <100 
bpm 
34% <100 
bpm 27% 12% 
Hays DB, R 3 15 AF A, 5 day ave. 
2gB x1 min, 
4g x 4 hrs. Placebo 
Yes, 
Digoxin 
BD=16 % 
AD=26% 
BD= 1% 
AD=18% 14.2% 37.5% 
Chiladakis 
R, SB 
2 
46 AF <12hrs 
2.5gBx15 
min,7.5g x 
6hrs 
Diltiazem 
25mgBx15 
min, 75mg x 
6hrs 
No 
NA, no 
difference 
NA, no 
difference 57% 22% 
Gullestad 
R, SB 
3 
64 AF and AFL 
<1 
week 
1.2gBx5min 
x2, then 
0.6g/hr 
Verapamil 
No At 4hrs, 
23.8% 
<100bpm 
At 4 hrs, 
58.3< 
100bpm 
57.1% 12.5% 
A= acute; AD: after digoxin; AF= atrial fibrillation; AFL= atrial flutter; B= bolus; BD=before digoxin; bpm=beats per minute; C= 
chronic DB=double blind; g= gram; hrs=hours; J= Jadad Score mg=milligrams; MgS04=Magnesium sulfate; min= minutes; NA= not 
available; NSR= normal sinus rhythm; P= prospective; Pts=patients; R= randomized; Retro= retrospective; SB= single blind; SS= 
Schindeler Score; SVT= supraventricular tachycardia; VR=ventricular rate 
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